Yang Xu, MD

CONTACT

Lead Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

•1. Aged 18 to 70 years (inclusive), irrespective of sex and race.
•2. Life expectancy greater than 12 weeks.
•3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 2.
•4. Meets the National Comprehensive Cancer Network (NCCN) criteria for relapsed or refractory disease, with a confirmed diagnosis of CD19-positive hematolymphoid malignancy
•5. Adequate hepatic, renal, and cardiopulmonary function
•6. Absolute lymphocyte count (ALC) ≥ 0.5 × 10⁹/L; Platelet count ≥ 50 × 10⁹/L; CD3-positive T-cell count ≥ 150 cells/μL

•1. Patients who, in the investigator's judgment at screening, require long-term use of immunosuppressive agents.
•2. History of cerebrovascular accident or convulsive seizures within 6 months prior to signing the informed consent form.
•3. Presence of other active malignant diseases besides the disease under study, with the exception of carcinoma in situ.
•4. Patients with severe cardiac disease, unstable systemic diseases, or chronic progressive neurological disorders, etc.
•5. Patients who have received CAR-T therapy or other genetically modified cell therapies prior to screening.
•6. Patients who have participated in other clinical studies within 1 month prior to screening.
•7. Evidence of central nervous system involvement at the time of screening.

Related studies

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

NCT06390319 · T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, and more

NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma

NCT06735690 · Acute Lymphoblastic Leukemia

NCT07191119 · Survivor of Childhood Cancer, Insomnia, and more

Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies